Determine the efficacy and safety of oral antiplatelet agents (ticagrelor versus clopidogrel) in patients with symptomatic peripheral artery disease (prior revascularization procedure or ABI < 0.80). Primary endpoints: cardiovascular death, myocardial infarction, stroke, bleeding.
Age > 50 years. Duration of study = approximately 36 months.
For more information, contact Schuyler Jones at 919-681-3945.